1.	Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670ADE03, NCT00481143
2.	Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Phase: Phase IV Type: Supportive care Status: Completed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AHU02, NCT00564941
3.	A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 2 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670A2409, NCT00171821
4.	Safety, Tolerability, and Efficacy of Deferasirox in MDS Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MDS0306, NCT00469560
5.	Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AUS02, NCT00117507
6.	Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AUS03, UCLA-0508054-01, NOVARTIS-CICL670AUS03, NCT00110266
7.	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CCCWFU 97710, NCI-2010-02228, NCT01273766